A novel SPECT/CT acquisition method utilizing lead-212 (212Pb) can accurately detect radiopharmaceutical biodistribution in a convenient manner. This technique has the potential to change practice and increase access for patients around the world by providing more precise treatment options.
A new study found that PET/MRI can accurately classify prostate cancer patients and help avoid unnecessary biopsies. The PRIMARY scoring system showed that over 80% of unnecessary biopsies could be avoided while missing only 12.5% of clinically significant prostate cancer cases.
Researchers developed a novel theranostic platform that combines PET imaging and therapeutic radionuclides to detect and treat ovarian cancer. The system uses the huAR9.6 antibody to target the MUC16 protein, showing promise for improved patient survival rates.
Researchers have developed a new method to trigger and image seizures in epilepsy patients, allowing for real-time data collection to tailor epilepsy surgery. This method is clinically feasible, convenient, and spares resources, providing valuable information for successful surgeries.
Researchers developed a novel PET tracer that can map fructose metabolism, differentiating diseased tissues from healthy ones. This non-invasive technique has the potential to detect diseases such as stroke, brain metastases, and heart attacks more sensitively.
New research reveals that radioguided surgery can effectively detect and remove metastatic pelvic lymph nodes in newly diagnosed prostate cancer patients. The procedure targets the prostate-specific membrane antigen, improving nodal staging to guide treatment recommendations.
Recent advances in permeating the brain-blood barrier hold promise for using radiopharmaceuticals to treat brain tumors. Theranostic approaches show encouraging preliminary results, particularly for meningiomas and pediatric brain tumors.
A retrospective study found that PRRT was effective in controlling hypoglycemia in 81% of patients with malignant insulinomas, enabling 58% to reduce medication use. The treatment resulted in improved symptom control and reduced potential drug side effects for over 80% of patients.
A novel PET imaging technique can detect active inflammation in the body before clinical symptoms arise, using a PET tracer that binds to proteins present on activated immune cells. This makes it easier for physicians to correctly diagnose and treat patients with rheumatoid arthritis.
A novel imaging approach has been shown to accurately identify sub-types of primary aldosteronism, an adrenal gland disorder. The technique provides a clearer picture of the adrenal glands, helping doctors decide whether surgery is necessary.
A novel PET imaging agent has been found to effectively identify medullary thyroid cancer (MTC) in preclinical and clinical studies. The compound demonstrates favorable tumor uptake and improved activity clearance from off-target tissues, potentially enhancing lesion detection and enabling targeted MTC radioligand therapy.
The Society of Nuclear Medicine and Molecular Imaging has published a new procedure standard/practice guideline for estrogen receptor imaging of breast cancer patients using FES PET. The guideline aims to promote the appropriate use of FES PET and enhance research, providing advantages in assessing tumor ER expression and predicting re...
A new PET imaging tracer has been developed to detect a common cancer gene mutation with high accuracy. The tracer targets the KRAS G12C protein, allowing for early identification of patients who can benefit from targeted therapy.
A new study found that Ga-68 FAPI PET imaging can effectively detect and stage pancreatic cancer, outperforming existing methods. The imaging modality also showed potential for future targeted radiopharmaceutical therapies.
Researchers have developed a novel PET radiotracer that enables early detection of inflammatory bowel disease (IBD) with high spatial and molecular specificity. The imaging tool targets the IBD biomarker IL12/23p40, providing detailed information for accurate diagnosis and treatment.
A study found that bone scans overstage prostate cancer at initial staging, leading to potential withholding of definitive therapy from patients. PSMA PET is more accurate than CT and bone scans for staging patients with prostate cancer.
A new AI tool provides fully automated, easy-to-use evaluation of brain tumors using amino acid PET scans. The deep learning-based segmentation algorithm assesses treatment response with quality comparable to that of an experienced physician.
Researchers found a single dose of ADC therapy combined with lovastatin reduced tumor volume rates similar to multiple doses in preclinical settings. Immuno-PET scans also monitored HER2 tumor levels after treatment, offering real-time insights into therapy response and potential personalized cancer treatments.
A new tau PET radiotracer, 18F-SNFT-1, demonstrates high sensitivity and specificity in identifying Alzheimer's disease. This improved tracer enables earlier diagnosis and potential therapeutic interventions.
A new imaging agent, 68Ga-ABY-025, can predict early metabolic response to HER2-targeted treatment in HER2-positive metastatic breast cancer patients. Whole-body PET/CT enables quantification of HER2 expression and predicts metabolic response, potentially sparing patients from unnecessary side effects.
A new nuclear medicine treatment has been shown to cure a highly lethal form of advanced intraperitoneal ovarian cancer in a preclinical setting. The therapy targets the HER2 protein and achieved high potency while maintaining an acceptable safety profile.
The Society of Nuclear Medicine and Molecular Imaging has issued a new consensus statement to standardize the selection and management of patients with metastatic castrate-resistant prostate cancer (mCRPC) treated with Lu-177 PSMA radionuclide therapy. The statement recommends performing PSMA PET within three months of treatment or sin...
A study found that PSMA PET/CT can accurately diagnose advanced prostate cancer in elderly patients without the need for a biopsy. The procedure reduced the number of biopsies and associated complications, while providing clinical suspicion-based staging data.
A novel PET perfusion radiotracer, 18F-flurpiridaz, demonstrates high diagnostic efficacy for obese patients with coronary artery disease, outperforming traditional imaging methods. The study showed improved sensitivity and specificity in diagnosing significant CAD, even at lower radiation doses.
A study using molecular imaging found that individuals with obesity respond differently to food cues than normal-weight individuals, with altered connectivity between brain networks. The research offers valuable insights into potential medical interventions for obesity, including novel drug treatments and behavioral therapies.
A newly discovered radionuclide-based agent (CB-2PA-NT) has shown high tumor uptake, sustained retention, and contrast in preclinical models. Targeting neurotensin receptors, CB-2PA-NT expands precision medicine for cancer diagnosis and treatment.
Cathy Sue Cutler is elected SNMMI president-elect to tackle talent shortages, funding issues and education gaps in the field. She aims to attract talent, enhance training opportunities and educate practitioners on theranostics for personalized medicine.
SNMMI has elected Jean-Luc C. Urbain as Vice President-Elect, who will focus on bringing new precision oncology nuclear therapies to the clinic. He aims to implement SNMMI's strategic plan, promoting its brand globally and increasing membership and financial support.
A study found that monitoring early-response biomarkers enables personalized dosing in prostate cancer treatment, improving patient outcomes. The approach allowed patients to take
The Society of Nuclear Medicine and Molecular Imaging has recognized ten new SNMMI Fellows, including Virginia Pappas as an honorary Fellow, for their excellence in volunteer service and scientific discovery. The SNMMI Fellowship is among the most prestigious formal recognitions available to long-time members.
Researchers developed a computational technique combining genomic and tau PET imaging data to identify four subtypes of Alzheimer's disease. The integrated approach also revealed top genes associated with each subtype. This personalized diagnostic technique has potential for broad utility across various diseases.
Helen Nadel, MD, FRCPC, has been named SNMMI President, aiming to raise awareness of and access to nuclear medicine, molecular imaging, and theranostics. She will focus on precision health, standardization, diversity, and increasing qualified professionals in the field.
Dr. Peter J. H. Scott has made significant contributions to radiopharmaceutical sciences through his development of new methods and technologies. He has also received numerous awards for his research, including the Sam Gambhir Trailblazer Award.
Umar Mahmood, a prominent researcher and leader in the field of nuclear medicine and molecular imaging, has been awarded the first annual SNMMI Minoshima-Pappas Transformational Leadership Award. His work focuses on developing new imaging methods for disease process examination and early therapeutic response assessment.
Dmitry Beyder has been elected as the president of the SNMMI-TS for 2023-24, aiming to increase technologists' roles in providing theranostics and nuclear medicine therapy. He brings extensive experience from various positions in the field.
SNMMI-TS elects Julie Dawn Bolin as president-elect, focusing on educating students about nuclear medicine careers and improving professional development. Bolin brings extensive experience in nuclear medicine technology and education.
Mullani, a pioneer in positron emission tomography (PET) prototype development, has been recognized for his significant contributions to the field. He developed new innovations in PET designs and published the first validation of time-of-flight information in PET to improve image quality.
Henry VanBrocklin, a professor at the University of California, San Francisco, has been recognized for his decades-long research on novel radiopharmaceuticals and their applications in medical imaging. He is being honored with the prestigious Paul C. Aebersold Award for his contributions to nuclear medicine.
A new PET radiotracer called <sup> 18 </sup> F-Cholestify has been developed to visualize metabolic cholesterol clearance in the brain. The tracer successfully visualized brain cholesterol metabolism in rats, non-human primates, and humans, showing promising results for studying neurodegenerative diseases.
Researchers have developed a new PET model to quantify cardiac amyloidosis, allowing for more accurate diagnoses and monitoring. The study found that a two-tissue reversible compartment model is the best method for quantifying 18F-flutemetamol myocardial uptake.
The global nuclear medicine initiative addresses the need for standardized educational curriculums to train physicians in nuclear theranostics procedures. The report highlights the rapid evolution of theranostic radiopharmaceuticals and emphasizes the importance of continuing medical education to maintain expertise.
A new approach uses pretherapy imaging and dosimetry to personalize radioactive iodine treatment for refractory differentiated thyroid cancer patients. The method allows researchers to calculate personalized dosage of treatment, resulting in improved outcomes.
A novel imaging agent has been developed to non-invasively detect pulmonary fibrosis in its early stages. The agent targets extracellular matrix fibers and has shown significant uptake in lungs with pulmonary fibrosis, matching histological results. This breakthrough could lead to earlier detection and better monitoring of the disease.
A recent meta-analysis shows that amino acid PET can accurately differentiate between recurrent brain metastases and treatment-related changes. This technology has the potential to reduce unnecessary invasive procedures and overtreatment in patients with cancer.
A new study has shown that FAPI PET imaging is superior to standard FDG PET in evaluating multiple types of cancer. A newly designed FAP-targeted treatment also suppressed tumor growth in several common cancers, suggesting a powerful tool for the field of clinical nuclear medicine.
A new PSMA PET scoring system, the tumor-to-salivary gland ratio (PSG score), can predict patient response to <sup> 177 </sup> Lu-PSMA therapy. Patients with high PSG scores had longer PSA progression-free survival and overall survival rates.
The Society of Nuclear Medicine and Molecular Imaging has issued new appropriate use criteria (AUC) for lymphoscintigraphy in sentinel node mapping and lymphedema/lipedema. The AUC covers four clinical categories of cancer, including breast cancer, skin cancer, and others, and addresses pediatric considerations.
A new nuclear medicine therapy has been shown to cure human non-Hodgkin lymphoma in an animal model, achieving a median survival of over 221 days. The treatment, [177Lu]Lu-ofatumumab, was found to quickly eliminate tumor cells and showed favorable in vitro characteristics.
A blood draw can provide valuable information on the effectiveness of peptide receptor radionuclide therapy for neuroendocrine cancer patients. Blood-based biomarkers PPQ and NETest were found to predict PRRT response with 96% and 90% accuracy, respectively. The study opens possibilities for tailoring treatment to individual patients.
A literature review published by the Society of Nuclear Medicine and Molecular Imaging reveals how nuclear medicine brain imaging can help evaluate biological changes causing chemotherapy-related cognitive impairment. The findings confirmed the impact of chemotherapy drugs on cognitive function and highlighted the utility of various SP...